MedCity News
OCTOBER 1, 2022
The metaverse holds promising potential to transform healthcare delivery for the better, according to a keynote talk delivered at MedCity’s Invest Digital Health conference. The speaker identified workforce training, patient experience, healthcare facilities and medical manufacturing as the main areas poised for disruption.
pharmaphorum
OCTOBER 6, 2022
An artificial intelligence-powered digital health worker has been unveiled by the World Health Organisation (WHO) as its latest tool for disseminating reliable health information to the public. Originally developed by New Zealand tech company Soul Machines with support of the Qatar Ministry of Health, the first version of the virtual health worker was used to combat misinformation about the pandemic.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
OCTOBER 7, 2022
Provention Bio and Sanofi US have signed a co-promotion agreement to launch the former’s lead investigational drug candidate, teplizumab for the delay in the onset of clinical type 1 diabetes (T1D). The agreement aids Provention in leveraging the capabilities and commercial resources of Sanofi to back teplizumab’s launch. The US Food and Drug Administration (FDA) is presently reviewing teplizumab for the delay of clinical T1D in people who are at risk.
PharmaTech
OCTOBER 3, 2022
Biopharma focuses on streamlining biomanufacturing and supply chain issues to drive uptake of cell and gene therapies.
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
MedCity News
OCTOBER 1, 2022
More than 7% of Hispanic Americans have a substance use disorder, but have less access to treatment than non-Hispanic Americans. The Spanish version of the app will provide the same services as English version, but with a focus on challenges experienced by the Latinx community.
pharmaphorum
OCTOBER 7, 2022
A UK study has found that Merck & Co’s oral COVID-19 therapy Lagevrio was unable to reduce hospitalisations compared to placebo in patients at higher risk from the virus, adding fuel to assertions in some quarters that its authorisation was premature. The 25,000-subject PANORAMIC trial conducted by researchers at Oxford University looked at the addition of a five-day course of Lagevrio (molnupiravir) to standard care in people aged over 50, or adults aged 18 and over with conditions th
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
Medgadget
OCTOBER 5, 2022
Imperial College London researchers created a conductive cotton thread that can undergo a computerized embroidery process for incorporation into commercially produced textiles, such as t-shirts and face masks. The thread, called PECOTEX, can be used to create wearable health sensors, such as heart rate monitors, breathing monitors and even gas sensors, including ammonia sensors for the breath, which can provide information on liver and kidney function.
MedCity News
OCTOBER 1, 2022
An INVEST Digital Health panel discussion on investment beyond the traditional hubs of venture capital investment, touched on the role of Zoom in making it easier to maintain relationships with startups across the country in places like Indiana, Utah, Colorado and beyond.
pharmaphorum
OCTOBER 3, 2022
Gaurav Kapoor, co-founder and executive vice president of Indegene, tells pharmaphorum how pharma can take lessons from the entertainment industry and prepare for the Metaverse to enhance content engagement. Pharma companies’ customer communication methods require reimagining as technology progresses. Kapoor says, now, pharma can learn from the on-demand nature of content distribution that Hollywood utilises and simultaneously prepare for future needs in content delivery. “One of our
Pharmaceutical Technology
OCTOBER 5, 2022
In 2010, two patients with end-stage refractory chronic lymphocytic leukaemia (CLL) were administered Novartis’ autologous anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy, Kymriah (tisagenlecleucel), as part of a Phase I trial. In March this year, it was reported that these two patients were still in remission, making this the longest known CLL remission after CAR-T therapy and demonstrating to the industry that long-term remission is indeed possible.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Medgadget
OCTOBER 3, 2022
A team at the University of Illinois at Urbana-Champaign has developed a DNA net system that can ensnare Sars-CoV-2 and bind to the notorious spike protein. The nets contain aptamers that bind the spike protein and emit an intense fluorescent signal once they’re bound together to the protein. This signal can be easily measured using a handheld fluorimeter.
MedCity News
OCTOBER 4, 2022
Google Cloud unveiled a new product suite to make medical imaging data more interoperable and useful via artificial intelligence. Hackensack Meridian Health has begun using it to detect metastasis in prostate cancer patients earlier, and Hologic is using it to strengthen its diagnostic platform that screens women for cervical cancer.
pharmaphorum
OCTOBER 4, 2022
The life sciences company Solid Biosciences is merging with the privately-held gene therapy company AavantiBio in a deal which is expected to result in a combined sum of $215 million in cash and investments – projected to be enough for funding into 2025. AavantiBio, a precision genetic medicine company that was bankrolled by Solid’s rival Sarepta back in 2020, focuses on neuromuscular and cardiac rare diseases.
Pharmaceutical Technology
OCTOBER 4, 2022
Pfizer has acquired commercial-stage biopharmaceutical firm Biohaven Pharmaceutical for $148.50 for each share or a total consideration of nearly $11.6bn in cash. In May, Pfizer entered a definitive agreement to acquire all outstanding shares of Biohaven which were not previously held by the former. . With the takeover, Biohaven became a wholly-owned Pfizer subsidiary.
Advertiser: ZoomInfo
Marketing technology is essential for B2B marketers to stay competitive in a rapidly changing digital landscape — and with 53% of marketers experiencing legacy technology issues and limitations, they’re researching innovations to expand and refine their technology stacks. To help practitioners keep up with the rapidly evolving martech landscape, this special report will discuss: How practitioners are integrating technologies and systems to encourage information-sharing between departments and pr
PM360
OCTOBER 1, 2022
Arising out of Calcium’s DEI initiatives, the healthcare marketing agency has launched the “I DON’T HAVE A BOX” campaign to drive awareness of the “race box” used in health data collection and its shortcomings in capturing true racial and ethnic diversity. Initially launched via website and social media, the campaign’s objective is to stimulate conversations around racial and ethnic “blind spots” in the healthcare system, ultimately translating into institutional change and improved health equit
MedCity News
OCTOBER 4, 2022
There is a dearth of professionals with licenses and training to provide care for seniors’ mental and behavioral health challenges — such as Alzheimer’s and other dementias, anxiety and depression. Seattle-based Rippl Care is seeking to change this. The startup just closed a $32 million seed funding round led by ARCH Venture Partners and General Catalyst.
Medgadget
OCTOBER 3, 2022
At the University of Minnesota, researchers have developed a soft robotic system that can ‘grow’ like a plant. The mechanism allows it to travel through difficult-to-access areas, such as the tortuous gastrointestinal tract or vasculature. The system works by extruding a liquid through an opening in the device, and at the same time a photopolymerization process results in the rapid solidification of the liquid into a solid structure.
Pharmaceutical Technology
OCTOBER 4, 2022
The type 2 diabetes (T2D) space recently witnessed a new approval: on 15 September, the European Commission (EC) authorised Eli Lilly’s Mounjaro (tirzepatide) for T2D patients. Mounjaro is a dual gastric inhibitory polypeptide (GIP)/glucagon-like peptide 1 (GLP-1) receptor agonist. This event is of paramount interest, and not only for T2D patients, as it could address vital unmet needs for other GIP/GLP-1 receptor agonist–treated diseases, including obesity.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
pharmaphorum
OCTOBER 4, 2022
The FDA has approved Swiss pharmaceutical company Roche’s first companion diagnostic for identifying those patients with HER2 low-metastatic breast cancer who are eligible for ENHERTU. The approval brings hope to many, with breast cancer having surpassed lung cancer to become the most commonly diagnosed cancer in the world: there are approximately 2.3 million new cases each year, and each year over 620,000 breast cancer patients will die.
MedCity News
OCTOBER 5, 2022
Third Harmonic Bio’s stock market debut was the only biotech IPO that crossed the $100 million threshold in the third quarter as the slowdown in IPO activity showed little sign of changing. Small deals continue to represent most of the IPO activity.
PharmExec
OCTOBER 1, 2022
Should pharma brands still maintain dedicated websites to engage HCPs? Are they effective and trustworthy sources of information that offer intuitive and helpful experiences for the user?
Pharmaceutical Technology
OCTOBER 3, 2022
The UK National Institute for Health and Care Excellence (NICE) has recommended zanubrutinib (Brukinsa) as an option to treat Waldenstrom’s macroglobulinaemia (WM) patients. With the latest development, zanubrutinib became the first WM drug to receive the recommendation for routine National Health Service (NHS) usage in England. The recommendation will also be applicable in Wales and Northern Ireland.
Advertisement
When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.
pharmaphorum
OCTOBER 6, 2022
Biological systems are hugely complex, with a staggering number of pathways interacting every millisecond. The downstream effects of just one biological change are enormous. So, when a new disease emerges, researchers have a near-impossible task working upstream from symptoms to identify the underlying cause and biological mechanisms causing disease.
MedCity News
OCTOBER 4, 2022
Save the date for INVEST 2023, which will take place on May 22-24 at the Ritz Carlton hotel in Chicago. The conference unites novel startups with active investors, highlights payer and provider perspectives, identifies challenges and opportunities in the life sciences, and describes healthcare’s overall transformation.
Impetus Digital
OCTOBER 5, 2022
In this customer story, we share how our client leveraged Impetus Digital’s large portfolio of life science-specific online collaboration tools and White-Glove services to: Conduct a needs assessment among embryologists and fertility specialists. Establish a small steering committee to co-create online course content related to updates in embryology and fertility medicine.
Pharmaceutical Commerce
OCTOBER 7, 2022
While all drug development efforts are fraught with peril, a growing number of biopharma companies—large and small—are staking a claim in the rare disease treatment space, chasing odds that could yield clinical and financial rewards.
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
pharmaphorum
OCTOBER 7, 2022
As we enter October and the Frontiers Health 2022 conference in Milan, we’re shining a spotlight on some of the Steering Committee members who have helped make the event what it is. Here we talk to Fredrik Debong, who cofounded MySugr in 2012 and sold it to Roche Diabetes Care five years later in an eight- to nine-figure deal. A cooling off in digital health investment.
MedCity News
OCTOBER 4, 2022
From July 2021 to July 2022, 1,216 prescription drugs saw price increases that soared past the inflation rate of 8.5% for that time period, one HHS report showed. Another reported that in 2021, the American healthcare system spent $603 billion on prescription drugs, of which $421 billion was spent on retail drugs.
Pharmaceutical Technology
OCTOBER 1, 2022
The US Food and Drug Administration (FDA) has granted approval for Amylyx Pharmaceuticals’ Relyvrio (sodium phenylbutyrate and taurursodiol) to treat adult patients with amyotrophic lateral sclerosis (ALS). Indicated for use as a monotherapy or along with currently approved therapies, Relyvrio can be administered orally by mixing a packet in eight ounces of water.
Copyright Clearance Center
OCTOBER 6, 2022
The post CCC Honored as Gold Winner in Customer Service Department of the Year Category From the Best in Biz Awards 2022 International appeared first on Copyright Clearance Center.
Advertiser: ZoomInfo
In times of economic uncertainty, account-based strategies are essential. According to several business analysts and practitioners, ABM is a necessity for creating more predictable revenue. Research shows that nearly three-quarters of marketers (74%) already have the resources needed to build successful ABM programs.
Expert insights. Personalized for you.
145 
Let's personalize your content